Novartis Reports Phase 2 JULIET Results for Kymriah in Relapsed/Refractory DLBCL

Novartis today announced results from the Phase 2 JULIET trial evaluating Kymriah (tisagenlecleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma. The trial demonstrated an overall response rate of 52%, with a complete response rate of 40%. These results led to FDA approval of Kymriah for relapsed/refractory DLBCL.